Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05551793 · ClinicalTrials.gov registry record · Phase 2
Regeneron AA Multicenter (Dupilumab)
A Phase 2 study of Alopecia Areata, sponsored by Emma Guttman.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 3
- Study locations
NCT05551793 is a Phase 2 study of Alopecia Areata that is actively recruiting participants, run by Emma Guttman. The registered enrollment target is 68 participants, below the 1,953-participant average among 26 other Alopecia Areata trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05551793, a Phase 2 study of Alopecia Areata, is actively recruiting participants, sponsored by Emma Guttman.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of atopy. Subjects will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks, with all subjects completing participation through Week 48 receiving an additional 48 weeks of dupilumab (through Week 96).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
Study Locations (3)
New York
- Icahn School of Medicine at Mount Sinai - New York
- UR Dermatology at College Town - Rochester
California
- University of California, Irvine - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2023-04-10 |
| Est. Completion | 2027-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05551793
The ClinicalTrials.gov registry entry for NCT05551793 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,953-participant average among 26 other Alopecia Areata trials with a reported enrollment target (97% lower). The listed sponsor is Emma Guttman, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05551793 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, California.
Frequently Asked Questions
What is clinical trial NCT05551793 about?
NCT05551793 is a clinical study titled "Regeneron AA Multicenter (Dupilumab)". This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers th...
What is the current status of trial NCT05551793?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2023-04-10. Estimated completion is 2027-11-03.
What conditions does trial NCT05551793 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT05551793?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05551793?
This trial is sponsored by Emma Guttman, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05551793 being conducted?
This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
-
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
RECRUITING · Phase 2
-
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.